Urology · Pain ManagementTrial Updateclinicalmid-term

Study Compares R.E.C.K vs Exparel for Pain Management in Robotic Nephrectomy

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 12:31:23 AM

Assessment confidence: 44% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial comparing R.E.C.K and Exparel for postoperative pain management in robotic nephrectomy is significant as it may redefine pain management protocols in surgical settings. A favorable outcome for R.E.C.K could lead to a shift in prescribing habits, impacting market dynamics and cost-effectiveness perceptions. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 9 ranked evidence items (1 high-relevance).

Strategic Assessment

If R.E.C.K proves superior or equivalent in efficacy, it could shift prescribing practices and impact Exparel's market share. The strongest clinical anchor is R.E.C.K vs Exparel in Robotic Nephrectomy (ClinicalTrials.gov), entity match (r e c k). In pain, 3 regulatory and 3 competitive items passed relevance filtering for R.E.C.K.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference. Results may influence the adoption of R.E.C.K as a cost-effective alternative to Exparel in surgical settings.

Regulatory Outlook

Regulatory risk is concentrated around FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA). Sub-indication match (pain). Relevant agencies in corpus: FDA, MHRA. The trial's results are unlikely to directly influence regulatory approvals but may inform future clinical guidelines and recommendations for pain management in surgical procedures.

Key Opportunities

Should R.E.C.K demonstrate comparable or superior efficacy, it could capture market share from Exparel, affecting revenue streams for the latter and altering competitive positioning in the pain management market.
If R.E.C.K proves superior or equivalent in efficacy, it could shift prescribing practices and impact Exparel's market share.

What Would Change This Assessment

This becomes more urgent if Monitor the trial's completion and publication of results for insights on pain management strategies.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDAhigh relevance
Sub-indication match (pain)
FDA document
View source
Warning on promoting newly licensed prescription-only medicines and unlicensed medicines for weight management
MHRAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
CDER Quality Management Maturity
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

R.E.C.K vs Exparel in Robotic Nephrectomy
ClinicalTrials.govmedium relevance
Entity match (r e c k)
FDA document
View source
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
ClinicalTrials.govmedium relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A Clinical Trial to Investigate the Efficacy and Safety of Plant-derived Cetylated Fatty Acids (CFA) on Knee Pain and Stiffness in Healthy Adults With Persistent Knee Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Prevalence and Risk Factors for Chronic Post-Surgical Pain Following Video-Assisted Thoracic Surgery : The EVATHO Prospective Bicentric Cohort Study.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Clinical Study of HRS-8797 in Healthy Participants
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study of Mental Health Care in People With Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Roche receives CE Mark for blood test to identify tuberculosis infection
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Bristol-Myers Squibb initiates Phase 3 trial for KarXT + KarX-EC in Alzheimer's agitation
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Cost-effectiveness analysis of apixaban compared with other oral anticoagulants for the treatment of non-valvular atrial fibrillation in Belgian healthcare setting.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

R.E.C.K
Exparel
Atrium Health Levine Cancer Institute

Commercial impact

medium

Should R.E.C.K demonstrate comparable or superior efficacy, it could capture market share from Exparel, affecting revenue streams for the latter and altering competitive positioning in the pain management market.

Regulatory impact

low

The trial's results are unlikely to directly influence regulatory approvals but may inform future clinical guidelines and recommendations for pain management in surgical procedures.

What to watch

Monitor the trial's completion and publication of results for insights on pain management strategies.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.